Cibus (CBUS) AI Stock Analysis

• Market Cap: $74.33M
• Dividend Yield: N/A
• Average Volume (3M): 600.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.15
• Revenue Growth: 63.66%
• EPS Growth: 36.72%
• Country: US
• Employees: 157
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.61
• Shares Outstanding: 52,540,527
• 10 Day Avg. Volume: 1,378,741
• 30 Day Avg. Volume: 600,304
• PEG Ratio: <0.01
• Price to Book (P/B): 0.70
• Price to Sales (P/S): 15.15
• P/FCF Ratio: -1.10
• Enterprise Value/Market Cap: 3.70
• Enterprise Value/Revenue: 56.80
• Enterprise Value/Gross Profit: 56.80
• Enterprise Value/Ebitda: -1.05
• 1Y Price Target: $20.00
• Price Target Upside: 1426.72% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $1.50 ▲(14.50% Upside)

Cibus's overall stock score is primarily impacted by its financial performance, which is hindered by ongoing losses and negative cash flows. While there are positive developments in commercialization and regulatory progress, these are overshadowed by the company's current financial challenges. Technical indicators suggest a bearish trend, and the valuation remains unattractive due to negative earnings. The earnings call provided some optimism with strategic initiatives, but significant risks remain.

Positive Factors

Revenue Growth Potential

The development of rice herbicide traits with significant revenue potential indicates a strong future revenue stream, enhancing market position and long-term growth prospects.

Regulatory Advances

Regulatory acceptance of gene-editing technologies supports Cibus's market expansion and product commercialization, reinforcing its competitive advantage in biotechnology.

Cost Management

Effective cost management through reduced expenses enhances operational efficiency, supporting long-term financial stability and profitability.

Negative Factors

Profitability Challenges

Ongoing net losses highlight persistent profitability challenges, which could impede financial health and require strategic adjustments to achieve sustainability.

Cash Flow Concerns

Negative operating cash flow indicates potential liquidity issues, limiting the company's ability to invest in growth initiatives and manage financial obligations.

EU Regulatory Delays

Delays in EU regulatory processes could hinder market entry and revenue realization in key regions, affecting long-term strategic goals and market expansion.

Cibus Business Overview & Revenue Model

Company Description

Cibus (CBUS) is a biotechnology company specializing in the development of innovative agricultural solutions, particularly focusing on crop protection and enhancement through its proprietary gene-editing technology. The company operates primarily in the agricultural sector, offering products that aim to improve crop yields, enhance resistance to pests and diseases, and reduce the need for chemical pesticides. Cibus is committed to sustainable agriculture practices and works to provide farmers with tools that are both effective and environmentally friendly.

How the Company Makes Money

Cibus generates revenue through the commercialization of its gene-edited agricultural products, which include seeds and crop traits that improve performance and resilience. The company typically licenses its technology to agricultural firms, receiving upfront fees and ongoing royalties based on product sales. Key revenue streams include partnerships with large agricultural companies, which allow Cibus to leverage their distribution networks and market access. Additionally, Cibus may benefit financially from grants and collaborations with research institutions focused on agricultural innovation.

Cibus Financial Statement Overview

Summary

Cibus is experiencing revenue growth but faces significant challenges in achieving profitability and positive cash flow. The company needs to focus on cost management and improving operational efficiency to enhance its financial health. While leverage is being managed better, the persistent losses and negative cash flows are areas of concern that require strategic attention.

Income Statement

Cibus shows a consistent increase in revenue, with a TTM revenue growth rate of 2.0%. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins over the periods. The gross profit margin is positive, but the high operating losses indicate significant challenges in managing costs and achieving profitability.

Balance Sheet

The company's debt-to-equity ratio has improved over time, indicating better leverage management. However, the return on equity remains negative, reflecting ongoing losses. The equity ratio suggests a reasonable level of equity financing, but the negative ROE highlights the need for improved profitability.

Cash Flow

Cibus has a negative operating cash flow, which is a concern for sustainability. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is covering net losses. However, the negative free cash flow growth rate and operating cash flow coverage ratio suggest cash flow challenges that need to be addressed.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.85M	4.26M	1.82M	157.00K	25.99M	23.85M
Gross Profit	4.85M	4.26M	1.42M	-1.38M	-2.57M	-11.28M
EBITDA	-262.49M	-241.63M	-314.58M	-15.21M	-25.43M	-41.53M
Net Income	-275.33M	-251.39M	-267.63M	-16.89M	-29.20M	-44.84M
Balance Sheet
Total Assets	346.20M	350.07M	544.41M	22.42M	37.19M	63.33M
Cash, Cash Equivalents and Short-Term Investments	36.46M	14.43M	32.70M	3.43M	13.82M	29.00M
Total Debt	35.42M	36.29M	24.62M	13.54M	17.88M	19.76M
Total Liabilities	271.72M	252.24M	206.12M	15.19M	23.06M	26.45M
Stockholders Equity	72.12M	92.16M	293.47M	7.23M	14.13M	36.88M
Cash Flow
Free Cash Flow	-53.74M	-58.85M	-50.53M	-20.88M	-19.31M	-45.46M
Operating Cash Flow	-52.95M	-58.04M	-46.21M	-19.36M	-18.81M	-43.67M
Investing Cash Flow	-795.00K	-808.00K	55.06M	-1.52M	11.20M	-13.48M
Financing Cash Flow	60.18M	40.60M	20.32M	9.99M	3.74M	15.41M

Cibus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.31
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBUS, the sentiment is Negative. The current price of 1.31 is below the 20-day moving average (MA) of 1.51, below the 50-day MA of 1.43, and below the 200-day MA of 1.82, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 41.67 is Neutral, neither overbought nor oversold. The STOCH value of 9.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CBUS.

Cibus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRVO	52 Neutral	$64.95M	-2.69	-54.21%	―	-19.44%	-492.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RPTX	47 Neutral	$76.47M	-0.69	-69.96%	―	-99.64%	-59.17%
XFOR	44 Neutral	$306.47M	―	-156.87%	―	2925.73%	-294.29%
CBUS	43 Neutral	$74.33M	-0.13	-160.72%	―	63.66%	36.72%
ABVC	43 Neutral	$68.53M	-12.64	-40.32%	―	56.52%	75.22%
OKYO	38 Underperform	$98.92M	―	―	―	―	―

Cibus Corporate Events

Cibus Appoints Carlo Broos as Chief Financial Officer

Cibus, Inc. has appointed Cornelis (Carlo) Broos as its Chief Financial Officer, effective retroactively from September 18, 2025. Mr. Broos, who has been with the company since 2011, previously served as the Interim CFO and has extensive experience in finance and accounting. This appointment is accompanied by an Executive Employment Agreement that outlines his compensation and severance benefits, reflecting the company’s commitment to strengthening its financial leadership.

The most recent analyst rating on (CBUS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus Appoints Kimberly A. Box to Board

On September 11, 2025, Cibus, Inc. appointed Kimberly A. Box to its board of directors. Ms. Box will serve on several committees, including the Compensation Committee, Nominating and Corporate Governance Committee, and a special committee evaluating strategic alternatives to maximize shareholder value. Her extensive experience includes roles at Gatekeeper Innovation, Hewlett Packard, and various other boards, bringing valuable expertise to Cibus. The appointment reflects Cibus’s commitment to enhancing its governance and strategic direction, potentially impacting shareholder value positively.

The most recent analyst rating on (CBUS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus, Inc. Earnings Call: Progress Amidst Challenges

Cibus, Inc. Earnings Call: Progress Amidst Challenges

Cibus, Inc. Reports Q2 2025 Financial Results

Cibus, Inc. is a leading agricultural technology company specializing in developing and licensing plant traits to seed companies, focusing on productivity and sustainability in the agricultural sector. In its latest earnings report, Cibus highlighted its strategic focus on rice herbicide tolerance traits and sustainable ingredients programs, with significant progress in commercialization efforts. The company reported a net loss of $26.6 million for the second quarter of 2025, a slight improvement from the previous year, attributed to cost reduction initiatives. Cibus successfully raised $27.5 million through a public offering, extending its cash runway as it advances towards revenue generation. Looking forward, Cibus remains optimistic about its commercialization prospects, particularly in Latin America and the U.S., and continues to benefit from a supportive global regulatory environment for gene editing technologies.